UBS Global Biopharma Conference - SEPTERNA INC
Explicit Guidance:
- SCP-479 (Hyperparathyroidism) Phase 1 Readout: Anticipated data release in Q1 2027.
- SCP-204 (Graves' Disease/Thyroid Eye Disease) Phase 1 Initiation: Expected to commence in Q1 2027.
- Phase 1 Data Share for SCP-204: Healthy volunteer data expected prior to end of 2027.
- Phase 2 Initiation (SCP-479): Targeted for the second half of 2026.
- Novo Partnership Milestone: First development candidate selected and planned for advancement (announced in quarterly earnings; collaboration started mid-2025).
Business-Segment Outlook:
- SCP-479 (PTH1R Agonist):
- Targeting 150 subjects in a Single/Multiple Ascending Dose (SAD/MAD) study in Australia, including a food effect study.
- Target PK/PD Biomarkers (Healthy Volunteers): Reduction in endogenous PTH levels by ~50%; increase in serum calcium by ~0.5 mg/dL (starting dose) and ~1.0 mg/dL (high dose) to match the performance of current injectable peptide standard (YorvPath).
- Half-life Projection: Observed half-life of 3–4 days (target range 40–80 hours), supporting once-daily dosing.
- SCP-204 (TSHR Antagonist):
- Targeting Graves' disease and thyroid eye disease (TED) via selective TSHR binding to block autoantibodies.
- Target PK/PD Biomarkers (Healthy Volunteers): Expected increase in endogenous TSH levels; suppression of thyroid hormones (T4) at higher doses.
- Half-life Projection: Estimated human half-life of 20–40 hours.
- Dosing Strategy: Aiming for dose-selective options to either normalize thyroid function or fully suppress it based on disease severity.
- SCP-631 (MRGPRX2 Negative Allosteric Modulator):
- Phase 1 completed (March 2027); currently between Phase 1 and Phase 2.
- Strategic Pivot: Moving away from large Phase 2 chronic spontaneous urticaria (CSU) studies toward smaller, signal-finding studies to validate mechanisms in new indications.
- New Indication Exploration: Prioritizing migraine (leveraging mast cell activation and PACAP agonism data), alongside interstitial cystitis and asthma.
- Osteoporosis Program (PTH Receptor Agonist):
- Developing a distinct short-acting oral compound (differentiation from long-acting SCP-479) to mimic anabolic bone formation effects of short-acting peptides.
- SCP-479 (PTH1R Agonist):
Market and Competitive Outlook:
- Hyperparathyroidism Market:
- Target Population: ~70,000–80,000 patients in the US (post-surgical).
- Unmet Need: Current standard of care (Calcium/Vit D) is insufficient for severe cases; injectable peptide (YorvPath) faces adherence issues due to daily injections.
- Competitive Differentiation: SCP-479 is the only oral PTH replacement in development. Differentiation from competitor Encallrate (CaSR agonist) via mechanism: SCP-479 replaces missing PTH directly (suitable for post-surgical patients), whereas Encallrate requires functional parathyroid tissue.
- Market Expansion: Oral therapy expected to expand treatable population to moderate patients and provide convenience for severe patients currently on injectables.
- Graves' Disease/TED Market:
- Unmet Need: High relapse rates with antithyroid drugs; limited novel therapies in decades; few options for mild TED and significant need for moderate-severe cases.
- Competitive Landscape: SCP-204 targets the root cause (autoantibodies at TSHR receptor) for both Graves' and TED simultaneously, a novel approach compared to current symptomatic treatments.
- Mast Cell (MRGPRX2) Market:
- Shifting strategy from broad CSU trials to targeted "signal-finding" studies in migraine to validate efficacy before larger commitments.
- Hyperparathyroidism Market:
Macro / Industry Outlook:
- Regulatory Strategy: Leveraging Phase 1 healthy volunteer data as a robust proof-of-concept for patient efficacy based on identical PTH receptor biology between healthy volunteers and patients.
- Clinical Development Efficiency: Planning to integrate chronic toxicology studies to enable open-label extension enrollment for Phase 3 patients immediately upon benefit confirmation.
Strategic Initiatives:
- Novo Collaboration: Ongoing partnership covering five targets (four concurrent programs); first candidate selected for forward development in late 2025/early 2026 (post-announcement).
- Pipeline Expansion: Advancement of a fourth program for osteoporosis, distinct from the hyperparathyroidism program due to specific dosing half-life requirements for bone anabolism.
- Platform Validation: Successful identification of two distinct binding pockets on GPCRs (PTH1R and TSHR) enabling oral small molecules to mimic peptide function, a breakthrough area historically difficult for competitors.
Risks and Headwinds to Outlook:
- Clinical Outcome Risks: Failure to achieve projected biomarker shifts (50% PTH reduction, 0.5–1.0 mg/dL calcium increase for SCP-479; TSH elevation and T4 suppression for SCP-204) could halt development.
- Safety Concerns: SCP-204 preclinical toxicology showed exaggerated on-target pharmacology (hypothyroidism), requiring careful dose titration in humans.
- Timing Delays: Phase 2 initiation for SCP-479 relies on completing chronic toxicology studies before Q2/Q3 2026; delays here could push patient enrollment.
- Competitive/Regulatory Uncertainty: Potential for Encallrate to demonstrate efficacy in post-surgical patients (currently considered mechanistically unsuitable) or for new competitive oral GPCR drugs to enter the space.
- Phase 1 Failure Risk: While healthy volunteer data is a strong predictor, clinical failure in patient populations remains a risk.
Management Tone on the Future:
- Confidence: High confidence in the "Native Complex Platform" success, emphasizing that SCP-479 and SCP-204 mimic peptide effects better than previous attempts.
- Strategic Pivot: Decisive and data-driven shift in the MRGPRX2 program, moving from large-scale CSU trials to focused migraine validation to conserve resources and identify signal.
- Differentiation: Strong conviction in the unique mechanism of SCP-479 for post-surgical patients compared to mechanism-based competitors (Encallrate).
- Market Outlook: Belief that oral therapies will significantly expand the treatable patient population in hypoparathyroidism and offer a novel, potentially curative approach for Graves' disease/TED.
Miscellaneous:
- Trial Designs: SCP-479 Phase 2 will utilize a titration protocol similar to YorvPath (dosing drug while reducing calcium/vitamin D supplements).
- Pharmacology: SCP-631 is characterized by a unique negative allosteric modulation mechanism with a slow off-rate, aiming for ~99% receptor occupancy.
- Company
- SEPTERNA INC
- Keywords
- SEPTERNA INC